Skip to content
Disclosery

Foresite Capital Management IV, LLC

Follow

13F filer, CIK 1704132, WEST HOLLYWOOD, CA

Foresite Capital Management IV, LLC reported $290,151,348 across 6 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-26-097103

Period
2026-06-30
Reported value
$290M
Holdings
6
Top 10 weight
100%
New
1
Sold out
3

Part of the filer group Foresite Capital Management VI LLC

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CYTKadded+211,400$18M
CRNXnew+150,000$5.61M
RLAYadded+250,000$4.68M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LYELexited-800,399-$16.1M
ALECexited-3,887,200-$8.36M
MAZEexited-156,901-$4.68M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001104659-26-097103, largest first. % of portfolio is the value over $290,151,348, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 4,397,881 shares; 2024Q4: 4,397,881 shares; 2025Q1: 4,410,581 shares; 2025Q2: 4,410,581 shares; 2025Q3: 4,778,581 shares; 2025Q4: 4,778,581 shares; 2026Q1: 4,778,581 shares; 2026Q2: 4,778,581 shares 4,778,581$165M56.95%0Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 458,295 shares; 2025Q4: 458,295 shares; 2026Q1: 503,295 shares; 2026Q2: 714,695 shares 714,695$60.9M20.98%+211,400Timeline
EIKNEIKON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,943,682 shares; 2026Q2: 1,943,682 shares 1,943,682$25.4M8.74%0Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,000,000 shares; 2024Q4: 1,000,000 shares; 2025Q1: 1,000,000 shares; 2025Q2: 1,000,000 shares; 2025Q3: 1,000,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 1,250,000 shares 1,250,000$23.4M8.06%+250,000Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 160,000 shares; 2025Q3: 160,000 shares; 2025Q4: 160,000 shares; 2026Q1: 160,000 shares; 2026Q2: 160,000 shares 160,000$9.66M3.33%0Timeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 150,000 shares 150,000$5.61M1.93%newTimeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
LYELLYELL IMMUNOPHARMA INC800,399$16.1Mshares
ALECALECTOR INC3,887,200$8.36Mshares
MAZEMAZE THERAPEUTICS INC156,901$4.68Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-097103 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001104659-26-097103 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001104659-26-062462 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001104659-26-015407 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001104659-25-112500 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001104659-25-076815 Quarter ended 2025-06-302025-08-12acceptance time not in the bulk data set
13F-HR 0001104659-25-049390 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001104659-25-013923 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001104659-24-118737 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001104659-24-088863 Quarter ended 2024-06-302024-08-13acceptance time not in the bulk data set
13F-HR 0001104659-24-061747 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0001104659-24-019703 Quarter ended 2023-12-312024-02-13acceptance time not in the bulk data set
13F-HR 0001104659-23-117291 Quarter ended 2023-09-302023-11-13acceptance time not in the bulk data set
13F-HR 0001104659-23-090055 Quarter ended 2023-06-302023-08-11acceptance time not in the bulk data set
13F-HR 0001104659-23-059498 Quarter ended 2023-03-312023-05-12acceptance time not in the bulk data set
13F-HR 0001104659-23-019778 Quarter ended 2022-12-312023-02-13acceptance time not in the bulk data set
13F-HR 0001104659-22-117992 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0001104659-22-089764 Quarter ended 2022-06-302022-08-12acceptance time not in the bulk data set
13F-HR 0001104659-22-059937 Quarter ended 2022-03-312022-05-13acceptance time not in the bulk data set
13F-HR 0001104659-22-020350 Quarter ended 2021-12-312022-02-11acceptance time not in the bulk data set
13F-HR 0001104659-21-137700 Quarter ended 2021-09-302021-11-12acceptance time not in the bulk data set
13F-HR 0001104659-21-105289 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR 0001104659-21-067103 Quarter ended 2021-03-312021-05-17acceptance time not in the bulk data set
13F-HR 0001104659-21-023083 Quarter ended 2020-12-312021-02-16acceptance time not in the bulk data set
13F-HR 0001104659-20-124783 Quarter ended 2020-09-302020-11-13acceptance time not in the bulk data set
13F-HR 0001104659-20-094444 Quarter ended 2020-06-302020-08-13acceptance time not in the bulk data set
13F-HR/A 0001104659-20-066873 Quarter ended 2020-03-312020-05-28acceptance time not in the bulk data set
13F-HR 0001104659-20-061251 Quarter ended 2020-03-312020-05-14acceptance time not in the bulk data set
13F-HR 0001104659-20-021578 Quarter ended 2019-12-312020-02-14acceptance time not in the bulk data set
13F-HR 0001104659-19-062963 Quarter ended 2019-09-302019-11-13acceptance time not in the bulk data set
13F-HR 0001144204-19-039332 Quarter ended 2019-06-302019-08-13acceptance time not in the bulk data set
13F-HR 0001144204-19-025824 Quarter ended 2019-03-312019-05-14acceptance time not in the bulk data set
13F-HR 0001144204-19-007307 Quarter ended 2018-12-312019-02-13acceptance time not in the bulk data set
13F-HR 0001144204-18-059272 Quarter ended 2018-09-302018-11-13acceptance time not in the bulk data set
13F-HR 0001144204-18-044638 Quarter ended 2018-06-302018-08-14acceptance time not in the bulk data set
13F-HR 0001144204-18-028464 Quarter ended 2018-03-312018-05-15acceptance time not in the bulk data set
13F-HR 0001144204-18-007694 Quarter ended 2017-12-312018-02-13acceptance time not in the bulk data set